跳至主要内容
临床试验/NCT06516263
NCT06516263招募中不适用

A Randomised Control Clinical Trial Investigating the Effect of L-PRF on Implant Stability and Marginal Bone Levels.

Dublin Dental University Hospital2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2024年6月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
50
试验地点
2
主要终点
Implant stability quotient

研究概览

简要总结

Osseointegration refers to the formation of a structure and functional bone-to-bone interface, without the interposition of soft tissue. Successful osseointegration is imperative to implant success and relies on a number of factors including implant design, material, surface and finish the bone status, surgical technique and implant loading conditions. Primary implant stability is the bio-mechanical stability achieved for implants at the time of placement and is achieved through micromovements of the implant. Following healing of the osteotomy site and formation of new bone a biological fixation of the implant to bone results and is referred to as secondary implant stability. Such as with osseointegration, there are several factors that affect primary implant stability including insertion torque, implant design, density of bone and surgical technique. To achieve future implant osseointegration, primary stability must first be accomplished.

Leukocyte and platelet rich fibrin (L-PRF) is formed by centrifuging venous blood using an IntraSpin® machine (U.S Food and Drug Administration approved and CE marked for in-vivo use) at 2700 revolutions per minute for 12 minutes. Following removal from the L-PRF tubes the fibrin clot is separated from the red blood cell clot. The fibrin clot is then transferred to the PRF box and the Xpression™ tray is placed over the fibrin clot and after 5 minutes the L-PRF membrane is ready for use.

During the traditional implant placement there is an osteotomy cut in practical terms is a controlled fracture of the bone resulting in rupture of local blood vessels which almost immediately sparks a cascade of healing including hemostasis, inflammation and proliferation of cells and tissue maturation. Our study will include Leukocyte platelet rich fibrin surrounding the implant at the osteotomy site which is a robust fibrin mesh which provides a progressive release of growth factors improving angiogenesis, osteoblastic proliferation, and cell differentiation. L-PRF utilization during implant placement attempts to expedite the process by delivering growth factors to the surface of the implant and surrounding bone promoting the healing process. Experimental research has shown that delivery of molecules or growth factors to an implants surface may increase osteoblast activity and improve functional integration of the implant.

Pre-clinical tests have shown that the utilization of platelet growth factors improve wound healing, proliferation of cells and implant osseointegration in animal models. Further pre-clinical studies have shown that L-PRF increased the rate and amount of new bone formation in rabbits.

Limited human tests in small populations not including the mandible have shown positive outcomes with improvement in implant stability when L-PRF was utilized during implant placement. High quality clinical evidence on this topic is limited and must be improved to allow clinicians to make evidence-based decisions on L-PRF utilization.

The proposed study will be a randomized control trial comparing the use of L-PRF in implant placement versus conventional implant placement. Considering the extra step of phlebotomy and time for centrifuging of the blood samples the literature must show a clinical benefit if this technique is to be utilized into the future. This study aims to add to available clinical evidence and address some of the limitations in current evidence to aid clinicians to make evidence-based decisions on whether to utilize LPRF to improve implant stability and hence earlier loading of implants.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Inclusion Criteria:
  • Patient Level
  • Male or Female, 18 years old or over
  • Capacity to provide informed consent
  • Willing to comply with study appointment schedule Willing to maintain a diary of symptoms
  • Planned for provision of dental implant(s) at Dublin Dental University Hospital Site Level
  • Location: maxilla and mandible
  • Sufficient bone volume for implant placement without the need for bone graft/augmentation; alveolar ridge of minimum 6mm width for standard implants (implant diameter 4mm) and of minimum 7mm for wider implants (implant diameter 5mm)

排除标准

  • Patient Level
  • Plaque score >20%
  • Bleeding score >20%
  • Tobacco smoking
  • Uncontrolled systemic disease
  • Use of systemic medications with an expected impact on bone healing (e.g. bisphosphonates)
  • Pregnancy or lactation
  • lack of capacity to give informed consent
  • Previous radiation to the head and/or neck Site Level
  • Insufficient bone volume for implant placement, requiring bone graft/augmentation

结局指标

主要结局

Implant stability quotient

时间窗: baseline, 3 months and 4-6 months

taken as Implant stability quotient value with an OSTELL device

次要结局

  • Clinical Marginal bone levels(Measured clinically at baseline and 3 months after implant placement at second stage surgery)
  • Radiographic marginal bone levels(at baseline 3 months and 4-6 months following implant placement)
  • Pain levels(After anaesthetic has worn off, 24 hours and 1 week)

研究者

发起方
Dublin Dental University Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Daniel Merrick

Principal Investigator

Dublin Dental University Hospital

研究点 (2)

Loading locations...

相似试验